Last updated: October 28, 2026
Elelyso, or taliglucerase alfa, is a plant-cell-produced enzyme replacement therapy for Gaucher disease type 1. The product was approved by the FDA in 2012 and is marketed by Protalix BioTherapeutics in the United States after Pfizer transferred commercial rights back to Protalix. Elelyso has a durable orphan-drug market but faces mature competition from Cerezyme, VPRIV, and oral substrate-reduction therapies. Its commercial outlook depends more on patient retention, geographic expansion, manufacturing economics, and pricing than on broad market growth.
What is Elelyso and who markets taliglucerase alfa?
Elelyso is a recombinant form of human glucocerebrosidase. It is administered by intravenous infusion and is indicated for adults and pediatric patients age 4 and older with confirmed type 1 Gaucher disease.
| Item |
Detail |
| Active ingredient |
Taliglucerase alfa |
| Brand |
Elelyso |
| Sponsor and manufacturer |
Protalix BioTherapeutics |
| Original commercial partner |
Pfizer |
| FDA approval |
May 1, 2012 |
| FDA application |
BLA 125368 |
| Indication |
Type 1 Gaucher disease |
| Administration |
Intravenous infusion |
| Therapeutic class |
Enzyme replacement therapy |
| Disease population |
Rare lysosomal storage disorder |
| Primary competitors |
Cerezyme, VPRIV, Cerdelga, generic and branded oral alternatives |
The product uses carrot-cell culture technology rather than mammalian-cell manufacturing. Protalix has positioned this platform as a lower-cost and scalable alternative to conventional mammalian-cell production, although commercial performance depends on reimbursement and market access rather than manufacturing cost alone.
Pfizer originally held global commercialization rights outside specified territories under a 2009 collaboration agreement. Protalix and Pfizer later amended the relationship, with Protalix assuming U.S. commercial responsibility beginning in 2021. Pfizer retained certain economic rights under the amended arrangement, including milestone and royalty provisions reported in Protalix filings.
How large is the Elelyso and Gaucher disease market?
The Gaucher disease market is a high-value, low-volume specialty market. Worldwide prevalence estimates vary, but diagnosed patients represent a small population concentrated in the United States, Israel, Europe, Brazil, and selected Latin American markets.
Treatment revenue is supported by several factors:
- Lifelong therapy for many patients.
- High annual treatment costs.
- Limited numbers of approved therapies.
- Specialist prescribing through metabolic-disease centers.
- Treatment persistence once a patient is stabilized.
- Reimbursement systems that support orphan-disease drugs.
The market is constrained by oral therapies, treatment switching, dose optimization, and the fact that not every diagnosed patient receives enzyme replacement therapy. Cerdelga, an oral substrate-reduction therapy, has expanded the treatment options for patients with appropriate CYP2D6 metabolizer status. Some patients also receive long-term treatment with VPRIV or Cerezyme.
Elelyso is therefore competing for existing treated patients rather than serving a rapidly expanding untreated population. New patient starts, geographic access, and switches from competing enzyme replacement therapies are more important than broad epidemiological growth.
What has been Elelyso’s revenue trajectory?
Protalix’s public filings show Elelyso as a recurring commercial product, but reported revenue has been influenced by inventory timing, distributor purchases, geographic sales, and the transfer of U.S. commercialization rights from Pfizer.
Public disclosures indicate that annual Elelyso product revenue has generally been in the tens of millions of dollars rather than the hundreds of millions associated with leading rare-disease blockbusters. During the 2020-2022 period, reported Elelyso revenue was approximately in the $40 million to $50 million annual range, subject to period-specific accounting and channel effects.[1][2]
| Period |
Commercial development |
Financial interpretation |
| 2012-2019 |
Pfizer-led commercialization in the U.S. |
Established a durable but smaller position against Cerezyme and VPRIV |
| 2020 |
Pfizer-Protalix commercial transition announced |
Created short-term channel and operating complexity |
| 2021 |
Protalix assumed U.S. commercial responsibility |
Increased Protalix’s direct revenue opportunity and selling costs |
| 2022 |
Elelyso remained a core commercial product |
Revenue was supported by recurring patients and international sales |
| 2023 onward |
Elelyso operated alongside Protalix’s broader product portfolio |
Financial profile became increasingly tied to portfolio diversification and new product launches |
The commercial transition improved Protalix’s control over pricing, patient services, and account management. It also shifted selling, distribution, and market-access expenses to Protalix. That means higher reported product revenue does not necessarily translate into proportional operating-profit growth.
Protalix’s financial trajectory is also affected by Elfabrio, its pegunigalsidase alfa product for Fabry disease. Elelyso remains important, but the company’s valuation increasingly reflects the potential contribution of newer assets rather than Elelyso alone.
How does Elelyso compare with Cerezyme, VPRIV, and Cerdelga?
Elelyso competes across three treatment categories: enzyme replacement therapy, oral substrate-reduction therapy, and established physician preference.
| Product |
Active ingredient |
Company |
Delivery |
Competitive position |
| Elelyso |
Taliglucerase alfa |
Protalix |
Intravenous infusion |
Plant-cell manufacturing; smaller commercial base |
| Cerezyme |
Imiglucerase |
Sanofi |
Intravenous infusion |
Long-established reference product |
| VPRIV |
Velaglucerase alfa |
Takeda |
Intravenous infusion |
Direct enzyme-replacement competitor |
| Cerdelga |
Eliglustat |
Sanofi |
Oral capsule |
Alternative for genetically suitable patients |
| Zavesca |
Miglustat |
Actelion/Janssen legacy product |
Oral capsule |
Narrower use and tolerability limitations |
Elelyso versus Cerezyme
Cerezyme benefits from long clinical and commercial experience. Physicians and treatment centers have extensive familiarity with imiglucerase, which creates switching resistance. Elelyso can compete through supply reliability, contracting, patient support, and pricing.
Elelyso versus VPRIV
VPRIV is the closest commercial substitute because both products are intravenous enzyme replacement therapies used in type 1 Gaucher disease. Head-to-head clinical differentiation is limited. Procurement terms, infusion schedules, supply continuity, and physician preference are central to competition.
Elelyso versus Cerdelga
Cerdelga offers an oral option, reducing infusion burden. It is not suitable for every patient because use depends on CYP2D6 genotype and other clinical factors. Elelyso retains relevance for patients who require enzyme replacement or cannot use substrate-reduction therapy.
When did Elelyso lose FDA exclusivity?
Elelyso’s principal statutory exclusivity periods have expired.
| Exclusivity type |
Approximate end date |
Effect |
| Orphan-drug exclusivity |
May 2019 |
Ended the seven-year orphan exclusivity period |
| Biologic reference-product data exclusivity |
May 2024 |
Ended the 12-year BPCIA reference-product exclusivity period |
| Patent protection |
Claim-specific |
May continue beyond regulatory exclusivity |
The FDA approved Elelyso on May 1, 2012. Orphan-drug exclusivity generally lasted seven years, placing the end of that period in 2019. Biologic reference-product exclusivity under the Biologics Price Competition and Innovation Act generally lasted 12 years, placing the end of the data-exclusivity period in 2024.[3]
The end of data exclusivity does not automatically create a biosimilar launch. A biosimilar applicant must obtain FDA approval, satisfy the statutory patent-notice process, establish manufacturing capability, and secure commercial access.
What is the Orange Book and Purple Book status of Elelyso?
Elelyso is a biologic, so its regulatory reference-product information is tracked through the FDA Purple Book rather than the Orange Book. The Orange Book primarily covers approved small-molecule drug products and associated listed patents.
The Purple Book identifies the reference biological product and any FDA-designated biosimilar or interchangeable biosimilar products. It does not function as a complete patent register. Patent rights affecting Elelyso must be evaluated through U.S. patent records, court filings, licensing agreements, and regulatory disclosures.
As of the public regulatory information available through 2024, Elelyso had no widely established FDA-approved biosimilar competitor comparable to the biosimilar markets for large biologics such as filgrastim, trastuzumab, or adalimumab.
What patent protections cover Elelyso?
Elelyso’s protection is based on a combination of biologic regulatory exclusivity, manufacturing technology, cell-culture processes, composition claims, formulations, and method-of-treatment claims.
The most commercially relevant patent categories are:
Taliglucerase alfa composition claims
These claims can cover the recombinant enzyme, specific amino-acid or glycosylation characteristics, and biologically active forms of glucocerebrosidase.
Plant-cell manufacturing patents
Protalix’s technology platform uses genetically engineered plant cells to produce recombinant proteins. Relevant claims may cover transformed cell lines, expression constructs, culture conditions, purification, and production methods.
Formulation and stability claims
Formulation patents may address concentration, buffers, excipients, storage conditions, reconstitution, and infusion stability. These claims can create additional barriers even after biologic data exclusivity ends.
Method-of-use claims
Method claims may cover treating type 1 Gaucher disease with taliglucerase alfa, dosing schedules, patient populations, or treatment-related parameters. Their enforceability depends on claim scope, prosecution history, and the conduct of a potential biosimilar applicant.
Geographic coverage
The key markets are the United States, Europe, Israel, Brazil, and other countries with Gaucher treatment infrastructure. Patent duration and enforcement differ by jurisdiction. European protection may involve a combination of European patents and national validations, while Brazil and other Latin American jurisdictions may have different examination and term-extension outcomes.
A precise freedom-to-operate analysis requires claim-level review of active patent families in each jurisdiction. Regulatory exclusivity has ended, but the end of exclusivity does not establish that every patent barrier has expired.
Which companies are challenging Elelyso?
No major FDA-approved biosimilar challenge to Elelyso had been publicly established through 2024. Potential competitive pressure comes primarily from existing branded products rather than a named biosimilar entrant.
The likely challenger categories are:
- Biosimilar developers targeting taliglucerase alfa or glucocerebrosidase.
- Manufacturers of alternative enzyme replacement therapies.
- Oral substrate-reduction therapy companies.
- Regional suppliers using price-based contracting.
- New Gaucher therapies that reduce infusion frequency or broaden oral treatment eligibility.
A biosimilar applicant would face a small but attractive specialty market. The commercial opportunity is limited by patient numbers, but recurring treatment and high annual revenue per patient can support a focused launch.
What generic entry risks exist for Elelyso?
Traditional generic entry is not the principal risk because Elelyso is a biologic. The relevant pathway is biosimilar approval under the Public Health Service Act.
The principal entry scenarios are:
| Scenario |
Timing |
Commercial impact |
| No biosimilar entry |
Near term |
Elelyso retains pricing and patient base |
| Single biosimilar entrant |
Medium term |
Contracting pressure and switching incentives increase |
| Multiple biosimilars |
Longer term |
Net price erosion and payer substitution become more likely |
| Oral-therapy expansion |
Ongoing |
Reduces the addressable enzyme-replacement population |
| Patent settlement |
Case-specific |
Can delay or define launch timing |
Biosimilar substitution is less automatic for infused enzyme replacement therapies than for many pharmacy-dispensed products. Hospital and specialty-pharmacy contracting, physician comfort, patient support, and payer policies will influence switching.
How strong is the Elelyso patent estate?
Elelyso has a commercially meaningful technology estate, but its strength is not equivalent to an extended, high-barrier patent position for a new molecular entity.
The estate’s strengths are:
- Proprietary plant-cell production know-how.
- Manufacturing complexity.
- Specialized analytical requirements.
- Limited number of qualified suppliers.
- Longstanding clinical experience.
- High switching friction in a rare-disease population.
Its limitations are:
- FDA regulatory exclusivity has expired.
- The product has been marketed for more than a decade.
- Competitors already offer clinically established alternatives.
- Biologic manufacturing patents may be designed around.
- Method-of-use claims may have narrower enforcement value than composition claims.
- A small market can justify a focused biosimilar development program.
Manufacturing know-how may be more important than any single patent. A biosimilar developer must reproduce a complex biologic within an acceptable analytical and clinical framework. That creates time and capital barriers, but it does not prevent entry indefinitely.
What litigation and settlement risks affect Elelyso?
Publicly disclosed litigation involving Elelyso has not established a major, market-defining patent dispute comparable to litigation surrounding large commercial biologics. The principal legal risks are future biosimilar patent litigation, licensing disputes, and challenges to manufacturing or formulation claims.
A biosimilar applicant could trigger the BPCIA patent-exchange process after submitting an application. The resulting dispute could address:
- Composition claims.
- Cell-line and expression-system claims.
- Manufacturing methods.
- Formulation claims.
- Treatment methods.
- Patent-term expiration.
- Damages and launch timing.
No broad public settlement framework has established a fixed biosimilar entry date for Elelyso. Any settlement would need to be assessed against the asserted patents, regulatory approval date, and possible antitrust constraints.
What is the FDA regulatory outlook for Elelyso?
Elelyso remains an FDA-approved biologic for type 1 Gaucher disease. Its regulatory value is supported by:
- An established safety and efficacy record.
- Pediatric use in patients age 4 and older.
- A defined rare-disease indication.
- Long-term treatment experience.
- Existing manufacturing and distribution infrastructure.
The regulatory risk is lower than the commercial risk. The more important questions concern payer coverage, patient retention, product supply, and whether Protalix can maintain competitive economics after the end of data exclusivity.
What is the financial outlook for Protalix and Elelyso?
Elelyso is likely to remain a stable recurring-revenue product rather than a high-growth asset. Its financial contribution depends on five variables:
- Retention of existing patients.
- New patient starts and switches.
- Net price after payer discounts.
- Protalix’s commercial and distribution expenses.
- Revenue contribution from newer products such as Elfabrio.
The base-case trajectory is mature and relatively defensive: stable revenue with modest pressure from competition and potential price concessions. Upside would come from international expansion, conversion of patients from other enzyme replacement therapies, and manufacturing cost control. Downside would come from biosimilar entry, payer-mandated switching, reduced treatment duration, or a shift toward oral therapies.
Elelyso’s revenue exposure is strategically important to Protalix because it provides commercial infrastructure and recurring cash flow. Its strategic value may exceed its absolute revenue because it supports relationships with metabolic-disease specialists, infusion centers, distributors, and reimbursement organizations.
How does Elelyso compare with Protalix’s newer products?
| Product |
Disease |
Commercial status |
Strategic role |
| Elelyso |
Type 1 Gaucher disease |
Established FDA-approved product |
Recurring base revenue |
| Elfabrio |
Fabry disease |
FDA-approved in 2023 |
Growth and portfolio expansion |
| PRX012 |
Alzheimer’s disease |
Clinical-stage asset |
Higher-risk pipeline option |
| Other Protalix programs |
Various rare diseases |
Development-stage |
Platform leverage |
Elelyso is more mature and commercially predictable than pipeline assets. Elfabrio provides Protalix with a second approved product and may improve sales leverage. The company’s financial trajectory is therefore increasingly a portfolio question rather than a single-product question.
Key Takeaways
- Elelyso is taliglucerase alfa, a plant-cell-produced enzyme replacement therapy for type 1 Gaucher disease.
- The FDA approved it in 2012; orphan exclusivity ended in 2019 and biologic data exclusivity ended in 2024.
- Elelyso is tracked in the FDA Purple Book, not the Orange Book.
- Protalix assumed U.S. commercial responsibility after Pfizer transferred commercial rights back to the company.
- Historical annual Elelyso revenue has generally been in the approximate $40 million to $50 million range.
- Cerezyme and VPRIV are the main intravenous competitors; Cerdelga is the leading oral alternative.
- No major FDA-approved Elelyso biosimilar had been publicly established through 2024.
- Manufacturing know-how, analytical complexity, patient retention, and specialty distribution are major barriers to entry.
- The product’s likely financial profile is mature and cash-generative, with moderate long-term erosion risk.
- Protalix’s future valuation increasingly depends on Elelyso stability combined with growth from Elfabrio and pipeline assets.
FAQs
Is Elelyso still protected by patents?
Potentially. Regulatory exclusivity has expired, but patent protection may continue for specific compositions, formulations, manufacturing methods, or treatment methods. The relevant rights must be assessed by patent family and jurisdiction.
Can a generic company copy Elelyso?
A conventional generic cannot use the standard small-molecule pathway. A competitor would generally need to pursue the FDA biosimilar pathway for the biologic reference product.
Is Elelyso interchangeable with Cerezyme or VPRIV?
FDA approval of one product does not automatically make it interchangeable with another. Treatment decisions depend on physician judgment, patient response, reimbursement, and product-specific regulatory status.
Does Elelyso have orphan-drug protection today?
The original seven-year U.S. orphan-drug exclusivity period ended in 2019. The product can continue to be marketed after that period, subject to patent, regulatory, and commercial competition.
What is the biggest commercial threat to Elelyso?
The main risks are biosimilar entry, payer-driven switching, competition from Cerdelga and other oral therapies, and pricing pressure from established enzyme replacement products.
References
-
Protalix BioTherapeutics, Inc. (2021). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2020. U.S. Securities and Exchange Commission.
-
Protalix BioTherapeutics, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
U.S. Food and Drug Administration. (2012, May 1). FDA approves new treatment for Gaucher disease. https://www.fda.gov/
-
Protalix BioTherapeutics, Inc. (2020). Protalix and Pfizer amend agreement for Elelyso commercialization rights. Company press release.
-
U.S. Food and Drug Administration. (2023). Elelyso prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125368s034lbl.pdf
